Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Thetis Pharmaceuticals LLC

Thetis Pharmaceuticals Presents New Preclinical and Clinical Data for TP-317 at ECCO 2025
From Thetis Pharmaceuticals LLC
Via Business Wire
Thetis Pharmaceuticals Secures an Additional $8.975 Million in Program-Related Investment Funds from the Helmsley Charitable Trust to Advance TP-317, an Oral BLT1 Agonist, into a Phase 1b Trial in Ulcerative Colitis Patients
From Thetis Pharmaceuticals LLC
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.